Insulet Corp
NASDAQ:PODD

Watchlist Manager
Insulet Corp Logo
Insulet Corp
NASDAQ:PODD
Watchlist
Price: 262.93 USD 0.35% Market Closed
Market Cap: 18.4B USD
Have any thoughts about
Insulet Corp?
Write Note

Insulet Corp
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Insulet Corp
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Insulet Corp
NASDAQ:PODD
Total Equity
$1.1B
CAGR 3-Years
31%
CAGR 5-Years
49%
CAGR 10-Years
30%
Becton Dickinson and Co
NYSE:BDX
Total Equity
$25.9B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
18%
Boston Scientific Corp
NYSE:BSX
Total Equity
$20.7B
CAGR 3-Years
8%
CAGR 5-Years
16%
CAGR 10-Years
12%
Stryker Corp
NYSE:SYK
Total Equity
$20.1B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
9%
Abbott Laboratories
NYSE:ABT
Total Equity
$39.3B
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
6%
Intuitive Surgical Inc
NASDAQ:ISRG
Total Equity
$15.6B
CAGR 3-Years
11%
CAGR 5-Years
15%
CAGR 10-Years
18%
No Stocks Found

Insulet Corp
Glance View

Market Cap
18.4B USD
Industry
Health Care

Insulet Corporation is a pioneering medical device company, primarily recognized for its innovative Omnipod Insulin Management System, which revolutionizes diabetes care. Founded in 2000, Insulet has focused on developing patch pump technology that offers a seamless, tubeless insulin delivery solution for individuals with insulin-dependent diabetes. This cutting-edge product allows users to manage their insulin delivery discreetly and conveniently, enhancing their quality of life and simplifying the complex regimen of diabetes management. As the prevalence of diabetes continues to rise globally, Insulet stands at the forefront of meeting a substantial medical need, capturing a significant market share with its user-friendly technology. As an investor, understanding Insulet’s growth trajectory and market potential is essential. The company has witnessed consistent revenue growth, driven by increased adoption of its Omnipod systems, and has expanded its product portfolio to include a new generation of devices that offer even greater functionality. Insulet is also heavily investing in research and development to further innovate its offerings, positioning itself competitively in the fast-evolving diabetes care market. With strong industry partnerships and a commitment to enhancing user experience, Insulet represents not just a promising investment in healthcare technology but also a company that is fundamentally improving the lives of millions.

PODD Intrinsic Value
96.69 USD
Overvaluation 63%
Intrinsic Value
Price

See Also

What is Insulet Corp's Total Equity?
Total Equity
1.1B USD

Based on the financial report for Sep 30, 2024, Insulet Corp's Total Equity amounts to 1.1B USD.

What is Insulet Corp's Total Equity growth rate?
Total Equity CAGR 10Y
30%

Over the last year, the Total Equity growth was 84%. The average annual Total Equity growth rates for Insulet Corp have been 31% over the past three years , 49% over the past five years , and 30% over the past ten years .

Back to Top